FILE PHOTO: Neuralink logo and Elon Musk photo are seen in this illustration taken, December 19, 2022. REUTERS/Dado Ruvic/Illustration/File Photo
(Reuters) -Neuralink, Elon Musk's brain-chip company, aims to enroll three patients to evaluate its device in a study expected to take several years to complete, according to details on the U.S. government's clinical trials database.
The company had sought to enroll 10 patients when it applied to U.S. regulators to begin clinical trials, Reuters reported last year. Neuralink is testing its implant designed to give paralyzed patients the ability to use digital devices by thinking alone, a prospect that could help people with spinal cord injuries.
